Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Matthew Langenderfer

Sports Medicine Cincinnati, OH Medical Doctor

NPI 1194731398 CMS profile 99500

8099 Cornell Rd, Cincinnati, OH 45249

Open in the dashboard

General payments

$2,194

19 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Matthew Langenderfer of Cincinnati, OH is reported in the CMS Open Payments database as having received $2,194 across 19 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 28th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $405 6
2024 General $164 5
2022 General $1,463 5
2021 General $151 2
2020 General $12 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Langenderfer
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Matthew Langenderfer were reported at $405. Among 2,404 Sports Medicine profiles paid that year, the median was $664 and the middle half received between $172 and $3,055.

Show as a table
Year Matthew Langenderfer Sports Medicine median Middle half National median
2019 $0 $1,176 $199–$4,249 $163
2020 $12 $708 $96–$2,890 $114
2021 $151 $1,213 $152–$3,994 $132
2022 $1,463 $1,230 $159–$3,998 $149
2023 $0 $584 $146–$2,836 $160
2024 $164 $628 $163–$3,168 $164
2025 $405 $664 $172–$3,055 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Legacy Ortho LLC $1,459 3 payments
  2. Zimmer Biomet Holdings, Inc. $633 11 payments
  3. Globus Medical, Inc. $49 2 payments
  4. DePuy Synthes Sales Inc. $41 2 payments
  5. Merck Sharp & Dohme Corporation $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Education $1,200 1 payment
  2. Food and Beverage $994 18 payments
Products named General payments · program years 2020–2025
  1. Persona Knees $247 4 payments
  2. PERSONA KNEE SYSTEM $167 1 payment
  3. Persona Knees $79 1 payment
  4. NexGen $79 1 payment
  5. ROSA-Knee $72 1 payment
  6. Anthem $49 2 payments
  7. Gel-One Cross-linked Hyaluronate $41 2 payments
  8. MONOVISC $41 2 payments
  9. ORTHOVISC $41 2 payments
  10. Comprehensive Shoulder System $15 1 payment
  11. Other $51 4 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

537

Median for Orthopedic Surgery: 203

Drug cost

$2,455

Median for Orthopedic Surgery: $1,433

Branded share of claims

0%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 36 $499
Meloxicam Generic 109 $317
Gabapentin Generic 86 $309
Amoxicillin Generic 115 $303
Methylprednisolone Generic 36 $195
Duloxetine Hcl Generic 16 $186
Tramadol Hcl Generic 48 $178
Diclofenac Sodium Generic 11 $110
Clindamycin Hcl Generic 23 $107
Mupirocin Generic 13 $91

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 79 billing codes

Paid by Medicare

$289,386

Of which drugs: $4,292

Medicare patients

616

Average age 74

Services billed

7,159

371 women, 245 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 71%
Ischemic heart disease 30%
Diabetes 25%
Chronic kidney disease 19%
Depression 18%
Atrial fibrillation 17%
Cancer 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 218 2,834 $2,037
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 44 162 $815
Injection, bupivicaine, not otherwise specified, 0.5 mg J0665 Office 174 1,587 $15

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

19 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record